GLORIA

GEOMAR Library Ocean Research Information Access

Ihre E-Mail wurde erfolgreich gesendet. Bitte prüfen Sie Ihren Maileingang.

Leider ist ein Fehler beim E-Mail-Versand aufgetreten. Bitte versuchen Sie es erneut.

Vorgang fortführen?

Exportieren
  • 1
    Online-Ressource
    Online-Ressource
    Wiley ; 2010
    In:  Protein Science Vol. 19, No. 2 ( 2010-02), p. 229-235
    In: Protein Science, Wiley, Vol. 19, No. 2 ( 2010-02), p. 229-235
    Kurzfassung: Human tissue transglutaminase (TGM2) is implicated in the pathogenesis of several neurodegenerative disorders including Alzheimer's, Parkinson's and expanded polyglutamine (polyQ) diseases. TGM2 promotes formation of soluble and insoluble high molecular weight aggregates by catalyzing a covalent linkage between peptide‐bound Q residues in polyQ proteins and a peptide‐bound Lys residue. Therapeutic approaches to modulate the activity of TGM2 are needed to proceed with studies to test the efficacy of TGM2 inhibition in disease processes. We investigated whether acetylation of Lys‐residues by sulfosuccinimidyl acetate (SNA) or aspirin (ASA) would alter the crosslinking activity of TGM2. Acetylation by either SNA and/or ASA resulted in a loss of 〉 90% of crosslinking activity. The Lys residues that were critical for inhibition were identified by mass spectrometry as Lys 444 , Lys 468 , and Lys 663 . Hence, acetylation of Lys‐residues may modulate the enzymatic function of TGM2 in vivo and offer a novel approach to treatment of TGM2 mediated disorders.
    Materialart: Online-Ressource
    ISSN: 0961-8368 , 1469-896X
    URL: Issue
    RVK:
    Sprache: Englisch
    Verlag: Wiley
    Publikationsdatum: 2010
    ZDB Id: 2000025-X
    SSG: 12
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 2
    Online-Ressource
    Online-Ressource
    American Society of Hematology ; 2004
    In:  Blood Vol. 104, No. 11 ( 2004-11-16), p. 3502-3502
    In: Blood, American Society of Hematology, Vol. 104, No. 11 ( 2004-11-16), p. 3502-3502
    Kurzfassung: FactorXIIIa (FXIIIa) plays an important role in regulating hemostatic and thrombotic events. FXIIIa modifies the structure of fibrin making the insoluble fibrin gel resistant to plasmin degradation. Methods to detect FXIIIa crosslinking of soluble fibrin(ogen) complexes (SFCs) are not readily available. The purpose of this study was to 1) develop a sensitive assay to detect FXIIIa crosslinked (XL)-SFCs designated: cryptic D-dimer assay, 2) determine whether soluble XL-SFCs are formed prior to formation of an insoluble clot, 3) determine whether soluble XL-SFCs circulated in human plasma and could be incorporated into a fibrin clot, 4) determine whether levels of soluble XL-SFCs are elevated in patients suspected of having intravascular coagulation. We postulated that the cryptic D-dimer antigen would be created by FXIIIa crosslinking of SFCs and could be detected after plasmin digestion. We added purified recombinant FXIIIa (119 nM) to afibrinogenemic plasma with varying concentrations of purified fibrinogen (10–200 μg/mL) and assayed for D-dimer antigen levels pre- and post- plasmin treatment. D-dimer levels were determined by a quantitative latex agglutination assay (MiniQuant® D-dimer, Ireland). The assay utilizes a monoclonal antibody specific for an epitope that is present on plasmin modified crosslinked D-dimer domain on either fibrinogen or fibrin. We found that generation of cryptic D-dimer antigen was a) dependent on FXIIIa, b) uncovered only after plasmin digestion and c) increased with escalating fibrinogen concentration. The level of cryptic D-dimer antigen increased from 0.45 μg/ml to 5.4 μg/ml in the presence of fibrinogen (10–200 μg/ml), FXIIIa and 5 mM calcium chloride. We had earlier confirmed that the cryptic D-dimer antigen could be detected in both EDTA and citrated plasmas and the exposure of this antigen was not modified by calcium present during plasmin digestion. We also determined that the cryptic D-dimer antigen was generated 150 sec before a visible clot appeared in recalcifed plasma in plastic tubes. We then investigated whether cryptic D-dimer antigen circulated in healthy individuals and if these levels changed in patients. Cryptic D-dimer antigen was detected (mean level 1 μg/ml, 〈 1% of plasma fibrinogen level) in ten normal plasma samples. In comparison, patients with elevated D-dimer by ELISA assay showed cryptic D-dimer mean level in excess of 5 μg/ml. Cryptic D-dimer levels increased with rising native D-dimer (no plasmin treatment) levels in patients. To assess the thrombogenic potential of SFCs with cryptic D-dimer antigens, we added reptilase (5 BU/ml) to plasma and examined whether the cryptic D-dimer antigen or native D-dimer could bind to a fibrin clot. We found that more than 70% of the cryptic D-dimer antigen was clottable (n=20) as compared to only 48 % of the native D-dimer (n=20). This suggests that the majority of cryptic D-dimer antigen is present on clottable SFCs. In conclusion, we developed an assay that can detect the ability of FXIIIa to modify SFCs before the appearance of a fibrin clot and may serve as a sensitive marker of intravascular fibrin formation. The cryptic D-dimer antigen is a novel analyte that is present on clottable SFCs and its levels increased in individuals experiencing intravascular blood coagulation. In addition, a basal level of FXIIIa activity exists in human plasma and that regulating this process could have an important impact on the fate of intravascular fibrin and thrombotic events.
    Materialart: Online-Ressource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Sprache: Englisch
    Verlag: American Society of Hematology
    Publikationsdatum: 2004
    ZDB Id: 1468538-3
    ZDB Id: 80069-7
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 3
    Online-Ressource
    Online-Ressource
    Springer Science and Business Media LLC ; 2013
    In:  Amino Acids Vol. 45, No. 4 ( 2013-10), p. 857-864
    In: Amino Acids, Springer Science and Business Media LLC, Vol. 45, No. 4 ( 2013-10), p. 857-864
    Materialart: Online-Ressource
    ISSN: 0939-4451 , 1438-2199
    Sprache: Englisch
    Verlag: Springer Science and Business Media LLC
    Publikationsdatum: 2013
    ZDB Id: 1480643-5
    SSG: 12
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 4
    In: Chemistry & Biology, Elsevier BV, Vol. 15, No. 9 ( 2008-09), p. 969-978
    Materialart: Online-Ressource
    ISSN: 1074-5521
    Sprache: Englisch
    Verlag: Elsevier BV
    Publikationsdatum: 2008
    ZDB Id: 2019089-X
    SSG: 12
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 5
    In: International Journal of Molecular Sciences, MDPI AG, Vol. 24, No. 13 ( 2023-06-30), p. 10935-
    Kurzfassung: Circulating uremic toxin indoxyl sulfate (IS), endothelial cell (EC) dysfunction, and decreased nitric oxide (NO) bioavailability are found in chronic kidney disease patients. NO nitrosylates/denitrosylates a specific protein’s cysteine residue(s), forming S-nitrosothios (SNOs), and the decreased NO bioavailability could interfere with NO-mediated signaling events. We were interested in investigating the underlying mechanism(s) of the reduced NO and how it would regulate the S-nitrosylation of tissue transglutaminase (TG2) and its substrates on glycolytic, redox and inflammatory responses in normal and IS-induced EC injury. TG2, a therapeutic target for fibrosis, has a Ca2+-dependent transamidase (TGase) that is modulated by S-nitrosylation. We found IS increased oxidative stress, reduced NADPH and GSH levels, and uncoupled eNOS to generate NO. Immunoblot analysis demonstrated the upregulation of an angiotensin-converting enzyme (ACE) and significant downregulation of the beneficial ACE2 isoform that could contribute to oxidative stress in IS-induced injury. An in situ TGase assay demonstrated IS-activated TG2/TGase aminylated eNOS, NFkB, IkBα, PKM2, G6PD, GAPDH, and fibronectin (FN), leading to caspases activation. Except for FN, TGase substrates were all differentially S-nitrosylated either with or without IS but were denitrosylated in the presence of a specific, irreversible TG2/TGase inhibitor ZDON, suggesting ZDON-bound TG2 was not effectively transnitrosylating to TG2/TGase substrates. The data suggest novel roles of TG2 in the aminylation of its substrates and could also potentially function as a Cys-to-Cys S-nitrosylase to exert NO’s bioactivity to its substrates and modulate glycolysis, redox, and inflammation in normal and IS-induced EC injury.
    Materialart: Online-Ressource
    ISSN: 1422-0067
    Sprache: Englisch
    Verlag: MDPI AG
    Publikationsdatum: 2023
    ZDB Id: 2019364-6
    SSG: 12
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 6
    In: Scientific Reports, Springer Science and Business Media LLC, Vol. 7, No. 1 ( 2017-11-23)
    Kurzfassung: Nitric oxide (NO) produced by endothelial cells in response to cytokines displays anti-inflammatory activity by preventing the adherence, migration and activation of neutrophils. The molecular mechanism by which NO operates at the blood-endothelium interface to exert anti-inflammatory properties is largely unknown. Here we show that on endothelial surfaces, NO is associated with the sulfhydryl-rich protein tissue transglutaminase (TG2), thereby endowing the membrane surfaces with anti-inflammatory properties. We find that tumor necrosis factor-α-stimulated neutrophil adherence is opposed by TG2 molecules that are bound to the endothelial surface. Alkylation of cysteine residues in TG2 or inhibition of endothelial NO synthesis renders the surface-bound TG2 inactive, whereas specific, high affinity binding of S-nitrosylated TG2 (SNO-TG2) to endothelial surfaces restores the anti-inflammatory properties of the endothelium, and reconstitutes the activity of endothelial-derived NO. We also show that SNO-TG2 is present in healthy tissues and that it forms on the membranes of shear-activated endothelial cells. Thus, the anti-inflammatory mechanism that prevents neutrophils from adhering to endothelial cells is identified with TG2 S-nitrosylation at the endothelial cell-blood interface.
    Materialart: Online-Ressource
    ISSN: 2045-2322
    Sprache: Englisch
    Verlag: Springer Science and Business Media LLC
    Publikationsdatum: 2017
    ZDB Id: 2615211-3
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 7
    Online-Ressource
    Online-Ressource
    American Association for Cancer Research (AACR) ; 2015
    In:  Cancer Research Vol. 75, No. 15_Supplement ( 2015-08-01), p. 5192-5192
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 75, No. 15_Supplement ( 2015-08-01), p. 5192-5192
    Kurzfassung: The epithelial to mesenchymal transition (EMT), which converts epithelial cells into an elongated, motile, and invasive phenotype, is considered to be a critical step in the dissemination of tumor cells. During EMT, the loss of E-cadherin (ECad) and upregulation of N-cadherin (NCad) or fibronectin (FN) have been most frequently described. FN binds integrin Alpha5 and is known for its upregulation in aggressive tumor cells. In addition, FN binds tissue transglutaminase (TGM-2) with high affinity (∼in nM) and plays a role in TGM-2 secretion. TGM-2, a multifunctional enzyme with transamidation or crosslinking, and GTP/ATP binding activities, is up-regulated in various malignant diseases, including lung cancer. In breast, cervical and ovarian cancers, TGM-2 has been shown to play a role in chemotherapy resistance and tumor metastasis during induction of EMT. TGM-2 overexpression results in the loss of epithelial features, up-regulation of mesenchymal markers, increased migration and invasion, and up-regulation of transcriptional repressors (e.g., ZEB1/2, Snail) known to mediate the EMT process. However, most of these studies were performed in aggressive tumor cells. In this study, we investigated the role of TGM-2 in TGFbeta-induced EMT process using NSCLC H358 cells. H358 cells express high levels of epithelial genes and are relatively resistant to TGFbeta induced EMT when compared to A549 cells. Particularly, H358 expresses barely detectable TGM-2 and FN. To investigate the role of TGM-2 during TGFbeta induced EMT, we constructed three isogenic cell lines with doxycycline (Dox)-inducible TGM-2 or C277A (an inactive mutant of TGM-2 with no transamidating activity) using InVitrogen's Flp-in TRex system. We found continuing treatment of 10 ng/ml TGFbeta for 6 days inducing H358 flp-in (vector control) cells to mescenchymal phenotype as demonstrated by the disappearance of Ecad, and the increased expression of NCad and FN. Under the same condition, Dox inducible TGM-2 and C277A facilitate the disappearance of Ecad, and Occludin and the appearance of Ncad. However, the expression of FN was undetectable in H358/TGM-2 and H358/C277A cells. As a result, H358/TGM-2 and H358/C277A remained localized and failed to migrate as demonstrated by a scratch wound healing assay. Seahorse mitochondria stress assay also demonstrated H358/TGM-2 and H358/C277A utilize more oxidative phosphorylation pathway than glycolytic pathway when compared with H358/flp-in, an indication of shifting cells to more normal phenotype. In summary, overexpression of TGM-2 (or inactive C277A mutant) inhibited the expression of FN and resulted in a less migratory H358 cells. Our results demonstrated that the role of TGM-2 during EMT in less aggressive epithelial cells such as H358 is different from its role in promoting EMT in other aggressive tumor cell; the suppression of FN might be a critical factor. Note: This abstract was not presented at the meeting. Citation Format: Thung S. Lai, Pin-Tsen Lin, Charles S. Greenberg, Harry A. Drabkin, Robert Gemmill. TGM-2 mediated downregulation of fibronectin during TGFb-induced epithelial-mesenchymal transition in lung cancer NCI-H358 cells. [abstract] . In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 5192. doi:10.1158/1538-7445.AM2015-5192
    Materialart: Online-Ressource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Sprache: Englisch
    Verlag: American Association for Cancer Research (AACR)
    Publikationsdatum: 2015
    ZDB Id: 2036785-5
    ZDB Id: 1432-1
    ZDB Id: 410466-3
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 8
    Online-Ressource
    Online-Ressource
    Elsevier BV ; 1997
    In:  Journal of Biological Chemistry Vol. 272, No. 26 ( 1997-06), p. 16295-16300
    In: Journal of Biological Chemistry, Elsevier BV, Vol. 272, No. 26 ( 1997-06), p. 16295-16300
    Materialart: Online-Ressource
    ISSN: 0021-9258
    Sprache: Englisch
    Verlag: Elsevier BV
    Publikationsdatum: 1997
    ZDB Id: 2141744-1
    ZDB Id: 1474604-9
    SSG: 12
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 9
    Online-Ressource
    Online-Ressource
    Elsevier BV ; 1999
    In:  Journal of Biological Chemistry Vol. 274, No. 35 ( 1999-08), p. 24953-24958
    In: Journal of Biological Chemistry, Elsevier BV, Vol. 274, No. 35 ( 1999-08), p. 24953-24958
    Materialart: Online-Ressource
    ISSN: 0021-9258
    Sprache: Englisch
    Verlag: Elsevier BV
    Publikationsdatum: 1999
    ZDB Id: 2141744-1
    ZDB Id: 1474604-9
    SSG: 12
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 10
    In: The FASEB Journal, Wiley, Vol. 21, No. 14 ( 2007-12), p. 4131-4143
    Materialart: Online-Ressource
    ISSN: 0892-6638 , 1530-6860
    URL: Issue
    Sprache: Englisch
    Verlag: Wiley
    Publikationsdatum: 2007
    ZDB Id: 1468876-1
    SSG: 12
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
Schließen ⊗
Diese Webseite nutzt Cookies und das Analyse-Tool Matomo. Weitere Informationen finden Sie hier...